{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T04:48:30Z","timestamp":1785473310859,"version":"3.56.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T00:00:00Z","timestamp":1738108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-024-01330-w","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:45:08Z","timestamp":1738154708000},"page":"437-444","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Baricitinib Provides Significant Improvements in Quality of Life and Functioning in Adults with Moderate-to-Severe Atopic Dermatitis with Baseline Body Surface Area\u2009\u2264\u200940% and Severe Itch"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-8728","authenticated-orcid":false,"given":"Matthias","family":"Augustin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa","family":"Izu-Belloso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Elise","family":"Kleyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Silvia\u00a0Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Grond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin R.","family":"Otero-Asman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad","family":"Reguiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshifumi","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"issue":"2","key":"1330_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125\u201337.","journal-title":"Ann Dermatol"},{"key":"1330_CR2","doi-asserted-by":"crossref","unstructured":"Paul C, et al. Factors predicting quality of life impairment in adult patients with atopic dermatitis: results from a patient survey and machine learning analysis. Dermatol Ther (Heidelb). 2023;13(4):981\u201395.","DOI":"10.1007\/s13555-023-00897-0"},{"issue":"10","key":"1330_CR3","doi-asserted-by":"publisher","first-page":"943","DOI":"10.36849\/JDD.2020.5422","volume":"19","author":"PA Lio","year":"2020","unstructured":"Lio PA, et al. Impact of atopic dermatitis lesion location on quality of life in adult patients in a real-world study. J Drugs Dermatol. 2020;19(10):943\u20138.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1330_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"1330_CR5","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1111\/exd.14389","volume":"30","author":"JT Sims","year":"2021","unstructured":"Sims JT, et al. Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease. Exp Dermatol. 2021;30(11):1650\u201361.","journal-title":"Exp Dermatol"},{"issue":"4","key":"1330_CR6","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1080\/09546634.2021.1914308","volume":"33","author":"PA Lio","year":"2022","unstructured":"Lio PA, et al. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. J Dermatolog Treat. 2022;33(4):2057\u201362.","journal-title":"J Dermatolog Treat"},{"issue":"3","key":"1330_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/DER.0000000000000895","volume":"33","author":"JM Hanifin","year":"2022","unstructured":"Hanifin JM, et al. The eczema area and severity index-a practical guide. Dermatitis. 2022;33(3):187\u201392.","journal-title":"Dermatitis"},{"issue":"1","key":"1330_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.anai.2021.03.019","volume":"127","author":"R Chovatiya","year":"2021","unstructured":"Chovatiya R, et al. Clinical phenotyping of atopic dermatitis using combined itch and lesional severity: a prospective observational study. Ann Allergy Asthma Immunol. 2021;127(1):83-90.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"1330_CR9","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12325-023-02528-8","volume":"40","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week 16. Adv Ther. 2023;40(8):3574\u201387.","journal-title":"Adv Ther"},{"key":"1330_CR10","unstructured":"European Medicines Agency. Olumiant (baricitinib). An overview of olumiant and why it is authorised in the EU. 2023. https:\/\/www.ema.europa.eu\/en\/documents\/overview\/olumiant-epar-medicine-overview_en.pdf."},{"key":"1330_CR11","doi-asserted-by":"crossref","unstructured":"Katoh N, et al. Pooled safety analysis of baricitinib in adult participants with atopic dermatitis in the Japanese subpopulation from six randomized clinical trials. Dermatol Ther. 2022;12(12):2765\u201379.","DOI":"10.1007\/s13555-022-00828-5"},{"key":"1330_CR12","doi-asserted-by":"crossref","unstructured":"Carrascosa J-M, et al. Baricitinib improvement across regions in atopic dermatitis patients with baseline body surface area up to 40% and severe itch. Dermatol Ther. 2024;14(6):1561\u201373.","DOI":"10.1007\/s13555-024-01171-7"},{"issue":"12","key":"1330_CR13","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"key":"1330_CR14","doi-asserted-by":"crossref","unstructured":"De Bruin-Weller M, et al. Treat-to-target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2): adv00402.","DOI":"10.2340\/00015555-3751"},{"issue":"1","key":"1330_CR15","first-page":"1","volume":"157","author":"A Costanzo","year":"2022","unstructured":"Costanzo A, et al. Long-term management of moderate-to-severe adult atopic dermatitis: a consensus by the Italian Society of Dermatology and Venereology (SIDeMaST), the Association of Italian Territorial and Hospital Allergists and Immunologists (AAIITO), the Italian Association of Hospital Dermatologists (ADOI), the Italian Society of Allergological, Environmental and Occupational Dermatology (SIDAPA), and the Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Ital J Dermatol Venerol. 2022;157(1):1\u201312.","journal-title":"Ital J Dermatol Venerol."},{"key":"1330_CR16","doi-asserted-by":"crossref","unstructured":"Wollenberg A, et al. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 phase 3 randomized trial. J Eur Acad Dermatol Venereol. 2021;35(7):1543\u201352.","DOI":"10.1111\/jdv.17278"},{"issue":"4","key":"1330_CR17","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.0022-202X.2005.23621.x","volume":"125","author":"Y Hongbo","year":"2005","unstructured":"Hongbo Y, et al. Translating the science of quality of life into practice: What do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659\u201364.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1330_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.21015","volume":"186","author":"G Yosipovitch","year":"2022","unstructured":"Yosipovitch G, et al. The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in baricitinib phase III trials. Br J Dermatol. 2022;186(6):1047\u20139.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01330-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01330-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01330-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T00:10:52Z","timestamp":1739837452000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01330-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1330"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01330-w","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"assertion":[{"value":"18 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Matthias Augustin served as a consultant or paid speaker for clinical trials sponsored by companies that manufacture drugs used for the treatment of alopecia areata, including AbbVie, Almirall, Eli Lilly, and Pfizer, and received support for attending meetings\/travel from Lilly. Maddalena Napolitano reports consulting fees from AbbVie, Lilly, LEO Pharma, Almirall, Sanofi; payment\/honoraria from AbbVie, Lilly, LEO Pharma, Almirall, and Sanofi; participation on data safety monitoring\/advisory boards from Lilly, Sanofi, LEO Pharma, AbbVie, and Almirall; and support for attending meetings\/travel from Lilly. Rosa Izu-Belloso reports payment as an advisor for Lilly, AbbVie, Sanofi, and LEO Pharma; grant support from Lilly; support for attending meetings\/travel from Lilly; and payment for speaking from Lilly. C. Elise Kleyn reports grants\/contracts from Eli Lilly and the Dowager Countess Eleanor Peel Trust; consulting fees from Eli Lilly, UCB, Almirall, Janssen, and La Roche Posay; payment\/honoraria from Eli Lilly, UCB, Almirall, Janssen, and La Roche Posay; and support for attending meetings\/travel from UCB, for participation on industry advisory boards for Eli Lilly, UCB, Almirall, Janssen, La Roche Posay, and Celgene, and for leadership\/fiduciary roles in other boards\/societies\/committees or advocacy groups for the Psoriasis Association, International Psoriasis Council, Psychodermatology UK, as Governor for the Northern Care Alliance, and as Visiting Professor of Bolton University. Silvia\u00a0Sabatino, Susanne Grond, and Joaquin R. Otero-Asman are employees and minor shareholders of Eli Lilly and Company. Chunyuan Liu is a consultant from Tigermed-BDM Inc. working for Eli Lilly and Company. Ziad Reguiai has received consulting fees from AbbVie, Almirall, Amgen, Celgene, Celltrion, Cerave, Incyte, GSK, Janssen Cilag, La Roche Posay, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB; payment\/honoraria from AbbVie, Almirall, Amgen, Avene, BMS, Celgene, GSK, Janssen-Cilag, LEO Pharma, Lilly, Medac, MSD, Novartis, La Roche Posay, Pierre Fabre Dermatologie, Pfizer, and UCB; and support for attending meetings\/travel from AbbVie, Almirall, Amgen, BMS, Janssen Cilag, LEO Pharma, Lilly, Novartis, Pfizer, Sanofi, and UCB. Toshifumi\u00a0Nomura reports payment\/honoraria from Eli Lilly, Sanofi, AbbVie, Pfizer, LEO Pharma, Torii, Ohtsuka, and Maruho.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All studies included in this analysis were conducted in accordance with the ethical principles of the Declaration of Helsinki. Written informed consent was obtained from all eligible participants before undergoing study-related procedures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}